Wednesday, April 29, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Perception vs. Comprehension: Public Understanding of the 2025 MAHA Report

This survey explores how the public engages with the May 2025 MAHA Report published by the White House. It aims to assess the relationship between political predisposition and objective understanding of the report.

Please indicate your level of agreement with the following statements

Strongly Disagree (1), Disagree (2), Neutral (3), Agree (4), Strongly Agree (5)

I have personally read or reviewed significant portions of the MAHA Report.
I believe I can accurately summarize the core findings of the MAHA Report.
My perception of the MAHA Report was formed before I read it in full.
I primarily learned about the MAHA Report through media outlets or social media commentary rather than the report itself.
My political beliefs influenced how I interpreted the MAHA Report’s credibility.
I initially judged the MAHA Report based on who released it (e.g., the White House) rather than its actual content.
I changed or adjusted my opinion after reading the MAHA Report for myself.
The MAHA Report reflects an evidence-based approach to health policy, regardless of political affiliation.
What are your overall thoughts on how the MAHA Report has been received by the public and media?
Discussions about the MAHA Report have become more about political ideology than public health.
What are your overall thoughts on how the MAHA Report has been received by the public and media?
.

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!